ATF3 Repression of BCL-X_L Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types.

ABSTRACT: Purpose: Histone deacetylase inhibitors (HDACi) are epigenome-targeting small molecules approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma. They have also demonstrated clinical activity in acute myelogenous leukemia, non-small cell lung cancer, and estrogen receptor-positive breast cancer, and trials are underway assessing their activity in combination regimens including immunotherapy. However, there is currently no clear strategy to reliably predict HDACi sensitivity. In colon cancer cells, apoptotic sensitivity to HDACi is associated with transcriptional induction of multiple immediate-early (IE) genes. Here, we examined whether this transcriptional response predicts HDACi sensitivity across tumor type and investigated the mechanism by which it triggers a

SUBMITTER: Chueh AC 

PROVIDER: S-EPMC5600837 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature